232 related articles for article (PubMed ID: 12196460)
21. Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction.
Kim YB; Kotani K; Ciaraldi TP; Henry RR; Kahn BB
Diabetes; 2003 Aug; 52(8):1935-42. PubMed ID: 12882908
[TBL] [Abstract][Full Text] [Related]
22. Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats.
Ogihara T; Asano T; Ando K; Chiba Y; Sekine N; Sakoda H; Anai M; Onishi Y; Fujishiro M; Ono H; Shojima N; Inukai K; Fukushima Y; Kikuchi M; Fujita T
Diabetes; 2001 Mar; 50(3):573-83. PubMed ID: 11246877
[TBL] [Abstract][Full Text] [Related]
23. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
[TBL] [Abstract][Full Text] [Related]
24. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects.
Park KS; Ciaraldi TP; Abrams-Carter L; Mudaliar S; Nikoulina SE; Henry RR
J Clin Endocrinol Metab; 1998 May; 83(5):1636-43. PubMed ID: 9589670
[TBL] [Abstract][Full Text] [Related]
25. Troglitazone improves insulin-stimulated glucose utilization associated with an increased muscle glycogen content in obese Zucker rats.
Oshida Y; Kako M; Nakai N; Shimomura Y; Li L; Sato J; Ohsawa I; Sato Y
Endocr J; 1999 Oct; 46(5):723-30. PubMed ID: 10670760
[TBL] [Abstract][Full Text] [Related]
26. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma.
Park KS; Ciaraldi TP; Lindgren K; Abrams-Carter L; Mudaliar S; Nikoulina SE; Tufari SR; Veerkamp JH; Vidal-Puig A; Henry RR
J Clin Endocrinol Metab; 1998 Aug; 83(8):2830-5. PubMed ID: 9709955
[TBL] [Abstract][Full Text] [Related]
27. Skeletal muscle insulin resistance in obesity-associated type 2 diabetes in monkeys is linked to a defect in insulin activation of protein kinase C-zeta/lambda/iota.
Standaert ML; Ortmeyer HK; Sajan MP; Kanoh Y; Bandyopadhyay G; Hansen BC; Farese RV
Diabetes; 2002 Oct; 51(10):2936-43. PubMed ID: 12351430
[TBL] [Abstract][Full Text] [Related]
28. Exercise and thiazolidinedione therapy normalize insulin action in the obese Zucker fatty rat.
Hevener AL; Reichart D; Olefsky J
Diabetes; 2000 Dec; 49(12):2154-9. PubMed ID: 11118020
[TBL] [Abstract][Full Text] [Related]
29. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
30. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes.
Kim YB; Nikoulina SE; Ciaraldi TP; Henry RR; Kahn BB
J Clin Invest; 1999 Sep; 104(6):733-41. PubMed ID: 10491408
[TBL] [Abstract][Full Text] [Related]
31. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias JP; Yu JG; Kruszynska YT; Olefsky JM
Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
[TBL] [Abstract][Full Text] [Related]
32. Muscle damage impairs insulin stimulation of IRS-1, PI 3-kinase, and Akt-kinase in human skeletal muscle.
Del Aguila LF; Krishnan RK; Ulbrecht JS; Farrell PA; Correll PH; Lang CH; Zierath JR; Kirwan JP
Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E206-12. PubMed ID: 10893341
[TBL] [Abstract][Full Text] [Related]
33. Contraction inhibits insulin-stimulated insulin receptor substrate-1/2-associated phosphoinositide 3-kinase activity, but not protein kinase B activation or glucose uptake, in rat muscle.
Whitehead JP; Soos MA; Aslesen R; O'rahilly S; Jensen J
Biochem J; 2000 Aug; 349 Pt 3(Pt 3):775-81. PubMed ID: 10903138
[TBL] [Abstract][Full Text] [Related]
34. Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells.
Konrad D; Rudich A; Bilan PJ; Patel N; Richardson C; Witters LA; Klip A
Diabetologia; 2005 May; 48(5):954-66. PubMed ID: 15834551
[TBL] [Abstract][Full Text] [Related]
35. Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.
Yokoyama I; Yonekura K; Moritan T; Tateno M; Momose T; Ohtomo K; Inoue Y; Nagai R
J Nucl Med; 2001 Jul; 42(7):1005-10. PubMed ID: 11438619
[TBL] [Abstract][Full Text] [Related]
36. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts.
Kellerer M; Kroder G; Tippmer S; Berti L; Kiehn R; Mosthaf L; Häring H
Diabetes; 1994 Mar; 43(3):447-53. PubMed ID: 7508875
[TBL] [Abstract][Full Text] [Related]
37. Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus.
Furuta M; Yano Y; Gabazza EC; Araki-Sasaki R; Tanaka T; Katsuki A; Hori Y; Nakatani K; Sumida Y; Adachi Y
Diabetes Res Clin Pract; 2002 Jun; 56(3):159-71. PubMed ID: 11947963
[TBL] [Abstract][Full Text] [Related]
38. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
39. Insulin-stimulated insulin receptor substrate-2-associated phosphatidylinositol 3-kinase activity is enhanced in human skeletal muscle after exercise.
Howlett KF; Sakamoto K; Yu H; Goodyear LJ; Hargreaves M
Metabolism; 2006 Aug; 55(8):1046-52. PubMed ID: 16839840
[TBL] [Abstract][Full Text] [Related]
40. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.
Ishizuka T; Itaya S; Wada H; Ishizawa M; Kimura M; Kajita K; Kanoh Y; Miura A; Muto N; Yasuda K
Diabetes; 1998 Sep; 47(9):1494-500. PubMed ID: 9726240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
